Mary‐Ellen Taplin

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer

The paper identifies immune spatial organization as a biomarker predicting metastasis risk in high-grade prostate cancer using computational pathology and H&E slides.

Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy

This study shows targeting a STING agonist to perivascular macrophages in ADT-treated prostate tumors delays castration resistance prostate cancer onset.

Patterns of Structural Variation Define Prostate Cancer Across Disease States

This study identifies distinct structural variation patterns in prostate cancer across disease states, defining clinically actionable subgroups based on whole genome profiling.

Transcriptional mediators of treatment resistance in lethal prostate cancer

This study identifies transcriptional states in mCRPC that mediate treatment resistance, including AR splicing heterogeneity, TGF-β signaling, and immune infiltration patterns.